20
Participants
Start Date
July 31, 2015
Primary Completion Date
October 31, 2015
Study Completion Date
November 30, 2015
Ranibizumab
\- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
Aflibercept
\- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
Ranibizumab and Aflibercept
\- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Aflibercept and ranibizumab
\- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Instituto de Olhos de Goiania
OTHER